Evelyn Neill serves as the Associate Director of Toxicology at REGENXBIO Inc., where she leverages her extensive background in biomedical science to drive innovative research in gene therapy. With over 15 years of experience, Evelyn has honed her expertise in experimental design, employing a diverse...
Evelyn Neill serves as the Associate Director of Toxicology at REGENXBIO Inc., where she leverages her extensive background in biomedical science to drive innovative research in gene therapy. With over 15 years of experience, Evelyn has honed her expertise in experimental design, employing a diverse array of models—from insects to mammalian systems—to explore critical aspects of endocrinology and cell signaling in both disease and developmental contexts. In her current role, she is responsible for overseeing nonclinical pharmacology and toxicology studies, ensuring that these investigations meet the rigorous standards necessary for regulatory submissions, including Investigational New Drug Applications (IND).
Evelyn’s work is pivotal in the development of novel gene therapy candidate drugs, where she acts as a nonclinical development representative on multiple project teams. Her collaborative approach facilitates seamless communication between internal stakeholders and external contract research organizations (CROs), thereby enhancing the efficiency and effectiveness of preclinical studies. Key projects under her leadership involve the assessment of safety and efficacy profiles for gene therapy applications, particularly in the context of heart failure, where innovative therapeutic strategies are urgently needed.
Her proficiency in techniques such as cell culture, biochemistry, and immunohistochemistry allows her to contribute significantly to the understanding of toxicological profiles and potential off-target effects of gene therapies. Evelyn’s dedication to advancing the field of gene therapy is matched by her commitment to fostering a culture of scientific excellence and innovation at REGENXBIO, making her an invaluable asset to the organization and the broader biomedical community.
